Early Antibiotic Exposure and Adverse Outcomes in Preterm, Very Low Birth Weight Infants - 21/11/18
, Alaina K. Pyle, MD 1, 2, 4, Phillip S. Wozniak, BS 1, 5, Linda S. Hynan, PhD 6, Pablo J. Sánchez, MD 1, 2, 5Abstract |
Objectives |
To determine whether antibiotic use in the first 14 postnatal days in preterm, very low birth weight (birth weight of ≤1500 g) infants is associated with risk after 14 days of age for late-onset sepsis, necrotizing enterocolitis (NEC), or death after controlling for severity of illness using the Clinical Risk Index in Babies II score, and determine whether duration of antibiotic exposure was associated with risk of adverse outcomes.
Study design |
This retrospective cohort study included very low birth weight infants born at ≤326/7 weeks of gestation admitted to the neonatal intensive care unit from September 2010 to June 2014. Infants were excluded if they had major congenital anomalies or culture-proven sepsis, NEC, or death during the first 14 days of life. Antibiotic exposure was recorded as days of therapy and length of therapy in days.
Results |
Of 374 infants, 70 (19%) had late-onset sepsis, NEC, or death after 14 days of age. The median number of antibiotic days of therapy and length of therapy were 5.5 and 3.0, respectively. In multivariate analysis after controlling for severity of illness, each antibiotic day of therapy was associated with a 1.24 times increased risk of sepsis, NEC, or death (OR, 1.24; 95% CI, 1.17-1.31). Risk was similar when length of therapy was used (OR, 1.47; 95% CI, 1.32-1.64).
Conclusions |
After controlling for severity of illness, each day of antibiotic therapy provided to preterm, very low birth weight infants in the first 2 weeks of age is associated with an increased risk of late-onset sepsis, NEC, or death.
Le texte complet de cet article est disponible en PDF.Keywords : neonate, neonatal intensive care unit, sepsis, stewardship
Abbreviations : AUC, CRIB-II, DOT, LOT, NEC, NICU, VLBW
Plan
| Supported by a Gerber Novice Researcher Award (#5200762201). The Gerber Foundation had no role or input into the study design; the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the paper for publication. The authors declare no conflicts of interest. |
|
| Portions of this study were presented at the Pediatric Academic Societies annual meeting, April 25-28, 2015, San Diego, California. |
Vol 203
P. 62-67 - décembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
